NEW YORK, Nov. 8 (GenomeWeb News) - Affibody and the National Cancer Institute plan to co-develop conjugates with Affibody molecules to be used for in vivo imaging, the Swedish company said today.
The agreement combines Affibody's internally developed technology with the US National Institute of Health's conjugation systems.
Affibody will develop engineered Affibody molecules specific for HER2, a receptor protein sometimes over-expressed in breast and ovarian cancers. NCI will conjugate the engineered molecules with detection molecules for evaluation.
Additional details were not disclosed.